Swedish Orphan Biovitrum has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's pharma deal with Biogen Idec.
Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the rFVIIIFc-XTEN-vWF fusion molecule in the collaboration.
Sobi is required to make a payment to Biogen Idec to include this program in the collaboration agreement.
Biogen Idec and Sobi are collaborators in the development and commercialisation of Eloctate(TM) and Alprolix(TM) for haemophilia A and B.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Biogen Idec
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity